Goldline Pharmaceutical IPO
smelistedAbout the company
Goldline Pharmaceutical Limited is engaged in the marketing of pharmaceutical products under its proprietary brand "Goldline". The company does not manufacture any products itself but operates through a third-party manufacturing model through contractual arrangements with manufacturers who manufacture products based on Goldline's market research, demand analysis, and specifications. Currently, the company is working with 15 manufacturers and 8 distributors. Its product portfolio spans across five divisions: 1) Goldline Pharma division consists of 42 products which cater to multi-speciality outpatient needs, including Orthopaedics, ENT, Gastroenterology, Neurology, and Urology. 2) The Goldline Cardinal division includes 54 products, which focus on cardio-diabetic therapies for chronic lifestyle diseases like cardiovascular disorders and diabetes, requiring long-term treatment. 3) The Goldline Aayushman division offers 18 products that target gynaecology and pediatric segments, addressing the healthcare needs of women and children. 4) The Goldline InLife division includes 22 products, including injectables and critical care products mainly used in hospital and ICU settings. 5) The Goldline Wellness division has 10 products that are designed to support and adjunct therapies for cancer patients and survivors, aiming at improving treatment tolerance and quality of life. Maharashtra is by far the biggest geographic market for the company's revenues, accounting for nearly 44 to 51% of total revenues during FY23 to 9MFY26, while Madhya Pradesh is the second largest market, making up about 26-29%, and the remaining geographic markets of Odisha, Jharkhand, Tamil Nadu, and Rajasthan make up relatively smaller amounts of revenues. Chhattisgarh saw substantial growth from 0.36% of revenue in FY23 to 3.96% in 9MFY26. The top customer contributed around 35 to 40% of total revenues across all periods, and the top 5 customers contributed ~77-79% of revenues. Approximately 99.8% to 100% of the revenues between FY23 and 9MFY26 were generated through wholesaler transactions; there are no significant direct retail sales.
GMP trend (Grey Market Premium by date)
| Date | GMP (₹) | Est. Listing | Change |
|---|---|---|---|
| 14 May | ₹15 | ₹58 | -10 |
| 13 May | ₹25 | ₹68 | +7 |
| 12 May | ₹18 | ₹61 | +1 |
| 11 May | ₹17 | ₹60 | +1 |
| 10 May | ₹16 | ₹59 | +1 |
| 09 May | ₹15 | ₹58 | +7 |
| 08 May | ₹8 | ₹51 | +8 |
| 07 May | ₹0 | ₹43 | 0 |
Strengths
- Operates in the pharmaceutical sector with steady demand potential
- Markets products under its own “Goldline” brand
- Asset-light business model through third-party manufacturing arrangements
- Wide product portfolio across multiple healthcare segments
- Revenue and profit showed consistent growth in FY25
- EBITDA margins improved in FY25 compared to FY24
- Healthy Return on Net Worth (RoNW) indicates improving profitability
- Established distribution and marketing network across multiple states
- Experienced promoters with pharma industry background
- IPO proceeds planned partly for debt reduction, which may improve balance sheet strength
Risks
- SME IPOs generally carry high volatility and low liquidity risk
- Business depends heavily on third-party manufacturers and suppliers
- Faces intense competition in the generic pharmaceutical industry
- Modest scale of operations compared to larger pharma companies
- Financial risk profile has historically been weak with moderate leverage
- Regulatory compliance risks remain high in the pharmaceutical sector
- Brand awareness appears limited compared to established pharma players
- Dependence on distributor and supplier relationships can affect operations if disrupted
- Final IPO valuation, GMP, and subscription response are still uncertain
- Any slowdown in product demand or regulatory issues may impact growth and margins
Financial performance (₹ Cr)
IPO Roadmap / Timeline
IPO Opens
Completed12 May 2026Bidding starts for all investor categories
IPO Closes
Completed14 May 2026Last day to place your bid
Basis of Allotment
Completed15 May 2026Share allotment finalised
Refund Initiation
Completed18 May 2026Refunds credited for non-allottees
Credit to Demat
Completed18 May 2026Allotted shares credited to demat account
Listing on Exchange
Completed19 May 2026Shares list on NSE / BSE
Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.
Lot size & minimum investment
| Investor Type | Min Lots | Min Shares | Min Amount | Max Lots | Max Amount | Notes |
|---|---|---|---|---|---|---|
| Retail / Individual | 1 | 3000 | ₹129,000 | 1 | ₹129,000 | 1 lot only |
| HNI | 2 | 6000 | ₹258,000 | 2 | ₹258,000 | Min 2 lots |
Shares reserved per category & allotment probability
| Category | Reservation | Shares Offered | Amount (₹ Cr) | Shares Bid | Subscribed | Allotment % |
|---|---|---|---|---|---|---|
| QIB | 50% | 1,428,572 | 6 | 0 | 0.00x | 100% |
| NII | 15% | 428,571 | 1.8 | 0 | 0.00x | 100% |
| Retail | 35% | 1,000,000 | 4.2 | 0 | 0.00x | 100% |
Retail is a lottery-based allotment when oversubscribed; QIB/NII get pro-rata. Probability ≈ 1 / subscription times (100% if under-subscribed).
